Halichondrin B Analog Synthesis via Chiral Catalysts
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The synthesis of halichondrin B analogs often involves costly purification steps and yields low due to the presence of unwanted by-products and impurities, particularly epimeric impurities, which can be challenging to remove effectively.
Innovation Solution
The development of crystalline forms of intermediates such as ER-076349 monohydrate and ER-809681, which serve as high-purity intermediates in multi-step syntheses, allowing for easier separation and reduction of impurities, and the use of these crystalline forms to characterize and remove epimeric impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional synthesis methods are used to produce halichondrin B analogs, then the synthesis process can be completed, but costly purification steps are required and yields are low due to unwanted by-products and impurities
Solution Approach 1:
The patent employs chiral catalysts in the synthesis process to pre-determine the stereochemistry of the product, preventing the formation of unwanted epimeric impurities before they occur. This preliminary action of establishing correct chirality during synthesis eliminates the need for subsequent purification steps to remove epimers, thereby increasing yield and reducing manufacturing complexity
Solution Approach 2:
The patent changes the chemical parameters of the synthesis process by introducing specific chiral catalysts and modifying reaction conditions to favor the formation of the desired stereoisomer. This parameter change in the synthesis approach transforms the process from one that produces mixtures requiring purification to one that directly yields high-purity product
2Manufacturing precision
If conventional synthesis methods are used, then synthesis can proceed, but epimeric impurities are difficult to remove effectively
Solution Approach 1:
By incorporating chiral catalysts at the beginning of the synthesis process, the correct stereochemistry is established in advance, preventing the formation of epimeric impurities. This preliminary establishment of chirality eliminates the need for complex purification processes to remove epimers, thereby improving manufacturing precision without increasing device complexity
Solution Approach 2:
The patent takes out the problematic epimeric impurities from the synthesis pathway by using chiral catalysts that selectively produce only the desired stereoisomer. This extraction of the impurity problem at the source, rather than attempting to remove it later, simplifies the overall process and improves purity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces the need for additional purification steps, decreases synthesis costs, and enhances the overall yield of halichondrin B analogs with potent anticancer properties, while also enabling effective characterization and removal of impurities.
Implementation Method 1
The development of crystalline forms of intermediates such as ER-076349 monohydrate and ER-809681, which serve as high-purity intermediates in multi-step syntheses, allowing for easier separation and reduction of impurities
Data Source
AI summary
The invention includes halichondrin B analogs having pharmaceutical activity; in some cases, crystalline forms thereof, and in some cases, halichondrin B analogs having a further utility as synthetic intermediates.